Trade Cidara Therapeutics, Inc. - CDTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.3196 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 22.0802 |
| Open | 21.7202 |
| 1-Year Change | 3045.12% |
| Day's Range | 21.1802 - 22.0302 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 21.3902 | -0.3300 | -1.52% | 21.7202 | 22.0702 | 21.0002 |
| Feb 20, 2025 | 22.0802 | -0.8900 | -3.87% | 22.9702 | 22.9702 | 20.5202 |
| Feb 19, 2025 | 23.3702 | -0.4000 | -1.68% | 23.7702 | 24.8202 | 23.0302 |
| Feb 18, 2025 | 23.8702 | 0.1500 | 0.63% | 23.7202 | 24.0802 | 23.4202 |
| Feb 14, 2025 | 23.7902 | 0.9200 | 4.02% | 22.8702 | 24.2902 | 22.2702 |
| Feb 13, 2025 | 23.3002 | 0.3900 | 1.70% | 22.9102 | 24.9002 | 22.7702 |
| Feb 12, 2025 | 23.4302 | 2.4500 | 11.68% | 20.9802 | 24.5102 | 20.9802 |
| Feb 11, 2025 | 21.7802 | 0.3100 | 1.44% | 21.4702 | 22.7402 | 20.9702 |
| Feb 10, 2025 | 21.6902 | 0.7000 | 3.33% | 20.9902 | 22.4102 | 20.9802 |
| Feb 7, 2025 | 21.5602 | 0.2900 | 1.36% | 21.2702 | 21.8502 | 20.9702 |
| Feb 6, 2025 | 20.8802 | 1.7100 | 8.92% | 19.1702 | 21.1902 | 19.1702 |
| Feb 5, 2025 | 20.1802 | 0.2100 | 1.05% | 19.9702 | 20.9902 | 19.9002 |
| Feb 4, 2025 | 20.0602 | 1.5900 | 8.61% | 18.4702 | 20.2002 | 18.4702 |
| Feb 3, 2025 | 18.8402 | 1.0600 | 5.96% | 17.7802 | 19.1902 | 17.7802 |
| Jan 31, 2025 | 18.4802 | 1.2600 | 7.32% | 17.2202 | 18.9202 | 17.2202 |
| Jan 30, 2025 | 17.8502 | 0.3800 | 2.18% | 17.4702 | 18.0402 | 17.0602 |
| Jan 29, 2025 | 17.7502 | -0.3800 | -2.10% | 18.1302 | 18.6402 | 17.6602 |
| Jan 28, 2025 | 18.5802 | 0.8100 | 4.56% | 17.7702 | 19.1102 | 17.5502 |
| Jan 27, 2025 | 18.0802 | -0.3700 | -2.01% | 18.4502 | 19.1102 | 18.0402 |
| Jan 24, 2025 | 18.7102 | -2.4900 | -11.75% | 21.2002 | 21.4702 | 18.5602 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cidara Therapeutics, Inc. Company profile
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The Company's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cidara Therapeutics Inc revenues increased from $12.1M to $49.6M. Net loss applicable to common stockholders decreased 43% to $42.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 9% to $1.9M (expense), Interest income (expense).
| Industry: | Bio Therapeutic Drugs |
6310 Nancy Ridge Dr Ste 101
SAN DIEGO
CALIFORNIA 92121-3209
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com